Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Impact on Quality of Life (QoL) of Persons with ME/CFS
- PMID: 39202496
- PMCID: PMC11356561
- DOI: 10.3390/medicina60081215
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Impact on Quality of Life (QoL) of Persons with ME/CFS
Abstract
Background and Objectives: We previously reported on the impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the QoL of persons with ME/CFS and their family members. Here, we present the findings of the impact on the QoL of individuals with ME/CFS whose family members did not participate in the survey. Materials and Methods: A prospective multinational online survey was disseminated via patient charities, support groups and social media. Persons with ME/CFS completed the EuroQoL questionnaire (EQ-5D-3L). Results: Data were analysed from 876 participants from 26 countries who reported a health care professional diagnosis of ME/CFS. In total, 742 participants identified as female, 124 male and 10 preferred not to say. The mean age of the participants was 47 years (range 18-82), and the mean time to diagnosis was 14 years. The mean overall health status on a visual analogue scale for people with ME/CFS was 36.4 (100 = best health). People with ME/CFS were most often affected by inability to perform usual activities (n = 852, 97%), followed by pain (n = 809, 92%), impaired mobility (n = 724, 83%), difficulty in self-care (n = 561, 64%) and least often affected by anxiety and depression (n = 540, 62%). Conclusions: The QoL of people with ME/CFS is significantly affected globally. There was no significant difference in quality of life compared with previously published data on those with ME/CFS who did have a family member complete the family member quality of life questionnaire (FROM16). Contrary to popular misconception, anxiety and depression are the least often affected areas in persons with ME/CFS who are most impacted by their inability to perform usual activities.
Keywords: chronic fatigue syndrome; myalgic encephalomyelitis; quality of life.
Conflict of interest statement
AYF is joint copyright owner of FROM-16, a family member was deputy chair of the NICE ME/CFS guideline committee. Outside of this study, Cardiff University receives royalties from some use of FROM-16: AYF receives a share of these under standard university policy. NLM is a director of Doctors with ME, expert witness for NICE NG206 2021 guidelines on ME/CFS education, former member of ME education working groups ICANCME (Canada), Forward ME and the Centre for Solutions (USA). NLM has authored an online e-learning module on ME/CFS and has received consultancy fees from Learn about ME Project and Ono Pharmaceuticals as well as honorarium from GW4 ME/CFS Carers Project. RE is a member of the Patient Advisory Group to the ME Research Collaborative (MERC PAG), a member of the ME/CFS Friendship Group in Gloucestershire, was a workshop participant in the James Lind Alliance ME/CFS Priority Setting Partnership, a supporter of Action for ME and The ME Association and is both a patient with ME/CFS and a family member of a patient with ME/CFS. JV and RS have no conflicts to declare.
Figures

Similar articles
-
Impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of people with ME/CFS and their partners and family members: an online cross-sectional survey.BMJ Open. 2022 May 2;12(5):e058128. doi: 10.1136/bmjopen-2021-058128. BMJ Open. 2022. PMID: 35501074 Free PMC article.
-
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Major Impact on Lives of Both Patients and Family Members.Medicina (Kaunas). 2021 Jan 7;57(1):43. doi: 10.3390/medicina57010043. Medicina (Kaunas). 2021. PMID: 33430175 Free PMC article.
-
Pain is associated with reduced quality of life and functional status in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.Scand J Pain. 2019 Jan 28;19(1):61-72. doi: 10.1515/sjpain-2018-0095. Scand J Pain. 2019. PMID: 30325738
-
A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis.Syst Rev. 2018 Dec 20;7(1):241. doi: 10.1186/s13643-018-0909-0. Syst Rev. 2018. PMID: 30572962 Free PMC article.
-
Management of chronic fatigue syndrome/myalgic encephalomyelitis in a pediatric population: A scoping review.J Child Health Care. 2020 Sep;24(3):411-431. doi: 10.1177/1367493519864747. Epub 2019 Aug 4. J Child Health Care. 2020. PMID: 31379194 Free PMC article.
Cited by
-
Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome-a clinical pilot study.Front Med (Lausanne). 2025 Jul 9;12:1607353. doi: 10.3389/fmed.2025.1607353. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40703261 Free PMC article.
-
Microbial Dysbiosis as an Emerging Pathology of Suicidal Behaviour? A Critical Review, Passing Through Depression to Chronic Pain.Ann Neurosci. 2025 Jul 19:09727531251349024. doi: 10.1177/09727531251349024. Online ahead of print. Ann Neurosci. 2025. PMID: 40693247 Free PMC article. Review.
References
-
- Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. National Institute for Health and Care Excellence (NICE); London, UK: 2021. Guideline NG206 N.
-
- Vyas J., Muirhead N., Singh R., Ephgrave R., Finlay A.Y. Impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of people with ME/CFS and their partners and family members: An online cross-sectional survey. BMJ Open. 2022;12:e058128. doi: 10.1136/bmjopen-2021-058128. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical